Serafin Morales Murillo

Llombart-Cussac, A; Cortes, J; Pare, L; Galvan, P; Bermejo, B; Martinez, N; Vidal, M; Pernas, S; Lopez, R; Muñoz M; Nuciforo, P; Morales, S; Oliveira, M; de la Peña L; Pelaez, A; Prat, A

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

LANCET ONCOLOGY 18 545-554. 01/04/2017.

[doi:10.1016/S1470-2045(17)30021-9]

Fernandez-Martinez, A; Pascual, T; Perrone, G; Morales, S; de la Haba, J; Gonzalez-Rivera, M; Galvan, P; Zalfa, F; Amato, M; Gonzalez, L; Prats, M; Rojo, F; Manso, L; Pare, L; Alonso, I; Albanell, J; Vivancos, A; Gonzalez, A; Matito, J; Gonzalez, S; Fernandez, P; Adamo, B; Muñoz M; Viladot, M; Font, C; Aya, F; Vidal, M; Caballero, R; Carrasco, E; Altomare, V; Tonini, G; Prat, A; Martin, M

Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer

Oncotarget 8 21930-21937. 28/03/2017.

[doi:10.18632/oncotarget.15748]

Gasol Cudos, A.; Morales Murillo, S.; Panades Siurana, M. J.; Vilardell Villellas, F.; Canosa Morales, C.; Mele Olive, J.; Iglesias Martinez, E.; Salud Salvia, A.

Change in treatment decisions according to Oncotype Dx Recurrence Score in node positive and negative, estrogen-receptor positive (ER+), HER2 negative breast cancer in a single institution

BREAST 32 92-93. 01/03/2017.

Prat, A.; Ortega, V.; Villagrasa, P.; Pare, L.; Galvan, P.; Oliveira, M.; Nuciforo, P.; Lluch, A.; Morales, S.; Amillano, K.; Lopez, R.; Gonzalez, R.; Manso, L.; Martinez, J.; Llombart, A.; De la Pena, L.; Di Cosimo, S.; Rubio, I. T.; Harbeck, N.; Baselga, J.; Cortes, J.

Efficacy and gene expression results from SOLTI1007 NEOERIBULIN phase II clinical trial in HER2-negative early breast cancer

CANCER RESEARCH 77 -. 01/02/2017.

[doi:10.1158/1538-7445.SABCS16-P1-09-09]

Gavila, J.; Perez-Garcia, J.; Calvo, I.; Ciruelos, E.; Munoz, M.; Virizuela, J. A.; Ruiz, I.; Andres, R.; Morales, S.; Perello, A.; Sanchez, P.; Garcia-Saenz, J. A.; Quero Guillen, J. C.; Gonzalez-Santiago, S.; Garau Llinas, I.; Gonzalez-Martin, A.; Sanchez de Ibarguen, B. Cantos; Zaragoza, K.; de la Pena, L.; Llombart-Cussac, A.; Oliveira, M.

Neoadjuvant non-pegylated liposomal doxorubicin plus paclitaxel, trastuzumab and pertuzumab in patients with HER2+breast cancer - Final results of the SOLTI OPTI-HER HEART study

CANCER RESEARCH 77 -. 01/02/2017.

[doi:10.1158/1538-7445.SABCS16-P4-21-05]

Aparicio, AP; Castan, JC; Pare, L; Galvan, P; Bermejo, B; Martinez, N; Vidal, M; Pernas, S; Lopez, R; Munoz, M; Nuciforo, P; Fasani, R; Morales, S; Oliveira, M; de la Pena, L; Pelaez, A; Llombart, A

PAM50 intrinsic subtype as a predictor of pathological complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer: First results of the PAMELA clinical trial

CANCER RESEARCH 77 -. 01/02/2017.

[doi:10.1158/1538-7445.SABCS16-S3-03]

Martin, M; Kahan, Z; Carrasco, E; Bartlett, CH; Casas, M; Gil-Gil, M; Munoz, M; Ciruelos, EM; Ruiz-Borrego, M; Margeli, M; Anton, A; Bermejo, B; Morales, S; Gal-Yam, E; Koehler, M; Garcia-Saenz, JA; de la Haba, J; Chacon, I; Zielinski, C

Phase III study of palbociclib (PD-0332991) in combination with endocrine therapy (exemestane or fulvestrant) versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with resistance to aromatase inhibitors. "The PEARL study" (GEICAM/2013-02)

CANCER RESEARCH 77 -. 01/02/2017.

[doi:10.1158/1538-7445.SABCS16-OT2-01-06]

Krop, IE; Mayer, IA; Ganju, V; Dickler, M; Johnston, S; Morales, SN; Yardley, DA; Melichar, B; Forero-Torres, A; Lee, SC; de Boer, R; Petrakova, K; Vallentin, S; Perez, EA; Piccart, M; Ellis, M; Winer, E; Gendreau, S; Derynck, M; Lackner, M; Levy, G; Qiu, JH; He, J; Schmid, P

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial

LANCET ONCOLOGY 17 811-821. 01/06/2016.

[doi:10.1016/S1470-2045(16)00106-6]

Llombart-Cussac, A; Ramos, M; Dalmau, E; Garcia-Saenz, JA; Gonzalez-Farre, X; Murillo, L; Calvo, L; Morales, S; Carañana V; Gonzalez, A; Fernandez-Morales, LA; Moreno, F; Casas, MI; Angulo, MD; Camara, MC; Garcia-Mace, AI; Carrasco, E; Jara-Sanchez, C

Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study

EUROPEAN JOURNAL OF CANCER 58 122-129. 01/05/2016.

[doi:10.1016/j.ejca.2016.01.015]

Gavilá, J.; Lopez-Tarruella, S.; Saura, C.; Muñoz, M.; Oliveira, M.; De la Cruz-Merino, L.; Morales, S.; Alvarez, I.; Virizuela, J.A.; Martin, M.

SEOM clinical guidelines in metastatic breast cancer 2015

CLINICAL & TRANSLATIONAL ONCOLOGY 17 946-955. 01/12/2015.

[doi:10.1007/s12094-015-1476-7]

Llombart-Cussac A; Bermejo B; Villanueva C; Delaloge S; Morales S; Balmaña J; Amillano K; Bonnefoi H; Casas A; Manso L; Roché H; Gonzalez-Santiago S; Gavilá J; Sánchez-Rovira P; Di Cosimo S; Harbeck N; Charpentier E; Garcia-Ribas I; Radosevic-Robin N; Aura C; Baselga J

SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer

BREAST CANCER RESEARCH AND TREATMENT 154 351-357. 01/11/2015.

[doi:10.1007/s10549-015-3616-8]

Gil-Gil, M.J.; Bellet, M.; Morales, S.; Ojeda, B.; Manso, L.; Mesia, C.; Garcia-Martínez, E.; Martinez-Jáñez, N.; Melé, M.; Llombart, A.; Pernas, S.; Villagrasa, P.; Blasco, C.; Baselga, J.

Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study

BREAST CANCER RESEARCH AND TREATMENT 151 597-606. 01/06/2015.

[doi:10.1007/s10549-015-3415-2]